Roberts Berzins has over a decade of experience in the financial management helping top-tier corporates shape their financial strategies and execute large-scale financings. He has also made significant efforts to institutionalize REIT framework in Latvia to boost the liquidity of pan-Baltic capital markets. Other policy-level work includes the development of national SOE financing guidelines and framework for channeling private capital into affordable housing stock. Roberts is a CFA Charterholder, ESG inves ...

Core Viewpoint - Silo Pharma, Inc. has announced a public offering of 3,333,338 shares of common stock at a price of $0.60 per share, along with associated warrants, aiming to raise approximately $2 million for general working capital purposes [1][2]. Group 1: Offering Details - The public offering includes 3,333,338 shares of common stock and two series of warrants (Series A-1 and Series A-2), each with an exercise price of $0.60 per share [1]. - The Series A-1 Warrants are exercisable upon issuance and will expire five years thereafter, while the Series A-2 Warrants will expire eighteen months after issuance [1]. - The closing of the offering is expected to occur on or about May 16, 2025, subject to customary closing conditions [1]. Group 2: Financial Aspects - The gross proceeds from the offering are expected to be approximately $2 million before deducting fees and expenses [2]. - The net proceeds will be used for general working capital purposes [2]. Group 3: Company Overview - Silo Pharma, Inc. is a developmental stage biopharmaceutical company focused on addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and CNS diseases [5]. - The company's portfolio includes innovative programs targeting PTSD, fibromyalgia, chronic pain, Alzheimer's disease, and multiple sclerosis [5]. - Research is conducted in collaboration with leading universities and laboratories [5].

Core Insights - Kartoon Studios reported a significant revenue increase of 138% year-over-year and 29% sequentially, achieving profitability in its Mainframe Animation Unit and Kartoon Channel! [1][6][24] Financial Performance - Total revenue for Q1 2025 reached $9.5 million, with a 56.4% year-over-year increase [25] - Production services revenue surged by 137.9% [6] - Operating loss improved by 51.1% year-over-year and 11.9% sequentially [6] - General and administrative expenses were reduced by 24.9% [6] - The company maintains a debt-free balance sheet with zero long-term debt [6][24] Business Growth and Strategy - Mainframe Studios serves as a consistent revenue driver, with over 90% of its 2025 budget revenue already under contract [9] - Kartoon Channel! is the 1 kids' streaming app on the Apple App Store, outperforming competitors like Netflix and Disney+ [12][17] - The platform's global reach extends to over 1.5 billion potential viewers across 61+ countries [13] Intellectual Property and Future Projects - Upcoming franchises include "A Hundred Acre Woods' Winnie & Friends" and "Stan Lee's The Excelsiors," expected to contribute significantly to revenue [20][22] - The creative team behind "Winnie & Friends" includes industry veterans known for successful franchises, enhancing its market potential [21][22] Operational Efficiency - The company has focused on optimizing operations, resulting in a leaner structure and improved financial metrics [4][23] - With four consecutive quarters of revenue growth, Kartoon Studios is positioned for sustained profitability by the end of 2025 [24]

Core Insights - BranchOut Food Inc. reported record Q1 2025 revenue of $3.2 million, a 118% year-over-year increase, marking a significant operational milestone with the full operation of its Peru facility [2][12][16] - The company is strategically positioned to benefit from U.S. tariffs on Chinese imports, providing a cost advantage over competitors reliant on Chinese sourcing [9][10] Financial Performance - Q1 2025 revenue reached $3.2 million, reflecting a 118% increase compared to the previous year [2] - The company anticipates being debt-free by the end of 2025, with substantial improvements in gross margin and cost structure expected to begin in Q2 [6][15] Operational Developments - The Peru facility, which is fully operational, supports over $40 million in annual production capacity and allows for better control over product quality and supply chain efficiency [2][6] - The facility's utilization is expected to improve significantly, with Q2 utilization already up more than 50% compared to Q1 [14] Strategic Partnerships and Market Expansion - BranchOut has expanded its partnership with the largest warehouse club in the U.S., generating nearly $3 million in sales in H1 2025 [3][6] - The company has entered a strategic partnership with MicroDried to lead sales in the industrial ingredient channel, projecting annual revenue of $5–6 million [6][8] Product Innovation and Direct-to-Consumer Strategy - BranchOut is expanding into the direct-to-consumer (DTC) channel, focusing on e-commerce and subscriptions, leveraging its proprietary GentleDry™ technology for competitive advantage [5][10] - The company has launched several innovative products, including Brussels Sprout Crisps and Carrot Sticks, which are now available nationwide [4][7] Market Positioning - With tariffs on Chinese imports at 30%, BranchOut is well-positioned to disrupt the freeze-dried snack market, competing against brands that heavily rely on Chinese sourcing [9][10] - The company is actively discussing replacing China-sourced private label SKUs with its own offerings to provide pricing stability and supply chain resilience [11]

Core Insights - Rackspace Technology successfully migrated the Housing Authority of the City of Austin's (HACA) technology infrastructure to Microsoft Azure and Microsoft 365, enhancing operational resilience and security [1][4] - HACA, a public-sector entity, provides essential housing services to low-income families and prioritizes operational continuity and security [2][3] - The transition to a cloud-based environment was prompted by critical downtime during a severe winter storm, which exposed vulnerabilities in HACA's on-premises infrastructure [3][4] HACA's Operational Needs - HACA requires technology to be available 99.9% of the time to support its mission of providing housing to vulnerable citizens [4] - The organization has approximately 240 staff members and manages various housing assistance programs through digital platforms [2] Migration and Improvements - The migration involved the seamless transition of 373 users and over 3.7 TB of data to Microsoft 365, significantly improving HACA's operational agility [4] - The new cloud infrastructure has enhanced business continuity, disaster recovery capabilities, and cybersecurity posture [4][5] Future Readiness - HACA's modernized technology stack provides a flexible and secure foundation for adopting emerging technologies and complying with evolving government standards [5] - The new environment allows HACA to respond proactively to future technological demands and community needs [5]

TROY, Mich., May 15, 2025 (GLOBE NEWSWIRE) -- KellyOCG®, the outsourcing and consulting group of Kelly (Nasdaq: KELYA, KELYB), has recognized its 11 top-performing suppliers around the globe with the 12th annual Kelly Supplier Excellence Awards. One supplier, US Tech Solutions, also received the Innovative Partner Award. “Every year our global supplier network raises the bar for delivering exceptional workforce solutions that empower our clients to innovate, grow and succeed,” Deb Timmerman, president, MSP, ...

Industry Overview - The medical instruments industry is experiencing a transformative phase driven by the rapid adoption of generative artificial intelligence (genAI) and digital therapeutics, which are expected to significantly impact the healthcare sector [1] - Since early 2023, there has been mass adoption of AI and the Internet of Medical Things in digital healthcare options across hospitals and healthcare settings [1] Generative AI Impact - GenAI is demonstrating its capabilities in various healthcare fields, including administrative tasks, technological discovery, and clinical trials, by analyzing complex genetic and molecular data [2] - The technology is anticipated to enhance predictive treatment options and smart hospital systems [2] Investment Opportunities - It is advisable to invest in stocks from the Zacks-defined Medical Instrument industry that have a favorable Zacks Rank, with five selected stocks showing double-digit returns amid market volatility [3][4] Selected Stocks - **DexCom Inc. (DXCM)**: Benefiting from strong performance in the Sensor segment, with expected revenue and earnings growth rates of 14.3% and 23.2% respectively for the current year [7][8] - **IDEXX Laboratories Inc. (IDXX)**: Demonstrating robust strategic execution with expected revenue and earnings growth rates of 5.8% and 14% respectively for the current year [9][11] - **NeuroPace Inc. (NPCE)**: Focused on developing a brain-responsive neuromodulation system for treating drug-resistant focal epilepsy, with expected revenue and earnings growth rates of 18.1% and 15.1% respectively for the current year [12][13] - **Fresenius Medical Care AG (FMS)**: Benefiting from strong organic growth and operational improvements, with expected revenue and earnings growth rates of 1.6% and 28.3% respectively for the current year [14][15] - **ClearPoint Neuro Inc. (CLPT)**: Specializing in minimally invasive surgical procedures in the brain, with expected revenue and earnings growth rates of 24.1% and 11.4% respectively for the current year [16][17]

Core Insights - Three stocks are highlighted with a strong buy rank and favorable value characteristics for investors to consider on May 15th [1][2][3] Group 1: Intercorp Financial Services (IFS) - Intercorp Financial Services provides financial products and services and has a Zacks Rank 1 (Strong Buy) [1] - The Zacks Consensus Estimate for its current year earnings has increased by 1.4% over the last 60 days [1] - The company has a price-to-earnings ratio (P/E) of 8.28, significantly lower than the S&P's 22.56, and possesses a Value Score of B [1] Group 2: Fox (FOX) - Fox produces and distributes news, sports, and entertainment content and also carries a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings has increased by 3.6% over the last 60 days [2] - The company has a price-to-earnings ratio (P/E) of 11.05, compared to the S&P's 22.56, and possesses a Value Score of B [2] Group 3: Pan American Silver (PAAS) - Pan American Silver is a mining company focused exclusively on silver and holds a Zacks Rank 1 [3] - The Zacks Consensus Estimate for its current year earnings has increased by 10.7% over the last 60 days [3] - The company has a price-to-earnings ratio (P/E) of 16.80, lower than the S&P's 22.56, and possesses a Value Score of B [3]

Company Performance - TriSalus Life Sciences, Inc. reported a quarterly loss of $0.33 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.20, representing an earnings surprise of -65% [1] - The company posted revenues of $9.17 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.04%, but showing an increase from $6.46 million in the same quarter last year [2] - Over the last four quarters, the company has not surpassed consensus EPS estimates and has topped consensus revenue estimates only once [2] Stock Performance - TriSalus Life Sciences, Inc. shares have declined approximately 2.2% since the beginning of the year, while the S&P 500 has gained 0.2% [3] - The current Zacks Rank for the stock is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $10.69 million, and for the current fiscal year, it is -$0.60 on revenues of $44.3 million [7] - The outlook for the Medical - Products industry, to which TriSalus belongs, is currently in the bottom 28% of over 250 Zacks industries, which may impact the stock's performance [8]

Core Viewpoint - Walmart reported quarterly earnings of $0.61 per share, exceeding the Zacks Consensus Estimate of $0.57 per share, and showing a slight increase from $0.60 per share a year ago, indicating a 7.02% earnings surprise [1][2] Financial Performance - The company achieved revenues of $165.61 billion for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 0.01%, and reflecting a year-over-year increase from $161.51 billion [2] - Over the last four quarters, Walmart has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance - Walmart shares have increased approximately 7.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.2% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.70, with projected revenues of $174.71 billion, while the estimate for the current fiscal year is $2.59 on revenues of $702.68 billion [7] - The Zacks Rank for Walmart is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Retail - Supermarkets industry, to which Walmart belongs, is currently ranked in the top 20% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]